Akari Therapeutics, Plc
AKTX
$1.21
$0.1059.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 78.35% | -23.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 131.91% | -66.66% | |||
| Operating Income | -131.91% | 66.66% | |||
| Income Before Tax | -30.29% | 61.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.29% | 61.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.29% | 61.70% | |||
| EBIT | -131.91% | 66.66% | |||
| EBITDA | -131.86% | 66.66% | |||
| EPS Basic | 18.11% | 70.42% | |||
| Normalized Basic EPS | 3.75% | 75.18% | |||
| EPS Diluted | 18.11% | 70.42% | |||
| Normalized Diluted EPS | 3.75% | 75.18% | |||
| Average Basic Shares Outstanding | 59.17% | 29.46% | |||
| Average Diluted Shares Outstanding | 61.67% | 27.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||